SE448603B - Oralt intagbart lekemedel innehallande en icke-steroid inflammationshemmande verksam bestandsdel och en eller flera fosfolipider - Google Patents

Oralt intagbart lekemedel innehallande en icke-steroid inflammationshemmande verksam bestandsdel och en eller flera fosfolipider

Info

Publication number
SE448603B
SE448603B SE7910371A SE7910371A SE448603B SE 448603 B SE448603 B SE 448603B SE 7910371 A SE7910371 A SE 7910371A SE 7910371 A SE7910371 A SE 7910371A SE 448603 B SE448603 B SE 448603B
Authority
SE
Sweden
Prior art keywords
active ingredient
steroidal
medicament according
phosphatidylcholine
acid
Prior art date
Application number
SE7910371A
Other languages
English (en)
Swedish (sv)
Other versions
SE7910371L (sv
Inventor
M Ghyczy
A Erdos
G Ritzmann
G Heidemann
Original Assignee
Nattermann A & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nattermann A & Cie filed Critical Nattermann A & Cie
Publication of SE7910371L publication Critical patent/SE7910371L/
Publication of SE448603B publication Critical patent/SE448603B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SE7910371A 1978-12-27 1979-12-17 Oralt intagbart lekemedel innehallande en icke-steroid inflammationshemmande verksam bestandsdel och en eller flera fosfolipider SE448603B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2856333A DE2856333C2 (de) 1978-12-27 1978-12-27 Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung

Publications (2)

Publication Number Publication Date
SE7910371L SE7910371L (sv) 1980-06-28
SE448603B true SE448603B (sv) 1987-03-09

Family

ID=6058494

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7910371A SE448603B (sv) 1978-12-27 1979-12-17 Oralt intagbart lekemedel innehallande en icke-steroid inflammationshemmande verksam bestandsdel och en eller flera fosfolipider

Country Status (13)

Country Link
US (1) US4332795A (de)
JP (1) JPS5589225A (de)
AT (1) AT369654B (de)
BE (1) BE880830A (de)
CA (1) CA1133395A (de)
CH (1) CH643739A5 (de)
DE (1) DE2856333C2 (de)
FR (1) FR2445146A1 (de)
GB (1) GB2039738B (de)
IT (1) IT1164550B (de)
NL (1) NL7909244A (de)
SE (1) SE448603B (de)
ZA (1) ZA797008B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2914788A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
DE2914789A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Injizierbare arzneimittel mit entzuendungshemmender wirkung
DE2952115C2 (de) * 1979-12-22 1982-05-06 A. Nattermann & Cie GmbH, 5000 Köln Rosmarinsäure-Phospholipid-Komplex
US4437155A (en) 1980-11-14 1984-03-13 Sperry Corporation Cache/disk subsystem with dual aging of cache entries
US4374082A (en) * 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
DE3374914D1 (en) * 1982-04-12 1988-01-28 Univ Texas Methods and compositions for treating gastro-intestinal ulcer diesease
GB2119244A (en) * 1982-04-30 1983-11-16 Alza Corp Potassium replacement therapy
US4666893A (en) * 1983-02-15 1987-05-19 St. Thomas Institute Methods of inducing resistance to bacterial and viral infections
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (en) * 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
DE3346525C2 (de) * 1983-12-22 1987-03-19 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-glycero-3-phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
DE3346526C2 (de) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
PT78628B (en) * 1984-05-02 1986-06-18 Liposome Co Inc Pharmaceutical composition with reduced toxicity
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
US5260284A (en) * 1987-02-17 1993-11-09 Board Of Regents, The University Of Texas System Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) * 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US4950656A (en) * 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
ES2306452T3 (es) * 1995-10-17 2008-11-01 Jagotec Ag Aporte de farmacos insolubles.
AUPN766496A0 (en) * 1996-01-22 1996-02-15 University Of New England, The Method and composition for the potentiation of anti-inflammatory drugs
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
WO1999040906A2 (en) * 1998-02-11 1999-08-19 Research Triangle Pharmaceuticals Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU764001B2 (en) 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
WO2013049749A2 (en) 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
WO2016185816A1 (ja) * 2015-05-18 2016-11-24 不二製油グループ本社株式会社 ＩＬ－１β産生抑制作用を有する食品添加用組成物
KR20220158031A (ko) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL32337C (de) *
IT1044768B (it) * 1969-04-03 1980-04-21 Italeapmaco Spa Supposte contenenti un principio attivo ascorbato di aminofemazione liofilizzato e processo per la loro preparazione

Also Published As

Publication number Publication date
DE2856333C2 (de) 1983-09-22
GB2039738A (en) 1980-08-20
AT369654B (de) 1983-01-25
FR2445146A1 (fr) 1980-07-25
SE7910371L (sv) 1980-06-28
JPS5589225A (en) 1980-07-05
FR2445146B1 (de) 1983-09-02
GB2039738B (en) 1983-04-13
JPS6320209B2 (de) 1988-04-26
DE2856333A1 (de) 1980-08-21
BE880830A (fr) 1980-04-16
CA1133395A (en) 1982-10-12
US4332795A (en) 1982-06-01
IT7928358A0 (it) 1979-12-21
CH643739A5 (de) 1984-06-29
NL7909244A (nl) 1980-07-01
ATA808379A (de) 1982-06-15
ZA797008B (en) 1980-12-31
IT1164550B (it) 1987-04-15

Similar Documents

Publication Publication Date Title
US4332795A (en) Inflammation-preventing pharmaceutical composition of oral administration
US4378354A (en) Inflammation-preventing pharmaceutical composition of oral administration
NL8002097A (nl) Parenteraal toedienbare stabiele geneesmiddel- oplossingen.
US5955451A (en) Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US5763422A (en) Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
Gupta et al. Pathologic effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in laboratory animals
US10179104B2 (en) PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
EP0010061B1 (de) Einen Mollusken-Extrakt enthaltende pharmazeutische Zusammensetzungen
WO1998013073A9 (en) METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDs AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN
PT2214480E (pt) Métodos de tratamento de esteato-hepatite não alcoólica (nash) utilizando produtos de cisteamina
CN1964715A (zh) 治疗狗的关节炎状况的方法
PT1526839E (pt) Formas farmacêuticas orais de fármacos líquidos com biodisponibilidade melhorada
Cimini et al. Gastroprotective effects of L‐lysine salification of ketoprofen in ethanol‐injured gastric mucosa
US20030219477A1 (en) Soft shell gelatin capsules containing non-steroidal anti-inflammatories
AU635869B2 (en) Pharmacological agent-lipid solution preparation
NL8002096A (nl) Injecteerbare stabiele geneesmiddeloplossing met ontstekingremmende werking.
EP1214940B1 (de) Methoden zur Erhöhung der Wirksamkeit von nicht-steroidalen antientzündlichen Arzneien und dazu verwendbare Zusammensetzungen enthaltend zwitterionische Phospholipide
US4528193A (en) Inflammation-preventing pharmaceutical composition of oral administration
BRPI0707698A2 (pt) preparaÇÕes nço esteroidais antiinflamatàrias orais lÍquidas e em pà para administraÇço a animais
CA2615836A1 (en) Lpa2 receptor agonist inhibitors of cftr
MX2014012862A (es) Composicion farmaceutica que comprende (1r,4r)-6'-fluoro-n,n-dimet il-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1-1'-pirano[3,4,b] indol]-4-amina y un oxicam.
KR20180014790A (ko) 염증성 질환 또는 병태를 치료하기 위한 조성물 및 방법
Courrèges et al. Protective effect of menhaden oil on renal necrosis occurring in weanling rats fed a methyl-deficient diet
ITMI20001741A1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e loro usi

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7910371-9

Effective date: 19930709

Format of ref document f/p: F